Abstract: The preventive or therapeutic agent for benign adult familial myoclonus epilepsy (BAFME) of the present invention contains an antisense oligonucleotide containing at least one of the base sequences of SEQ ID NOS: 1 to 4. Among the antisense oligonucleotides, oligonucleotide consisting of at least one of the base sequences of SEQ ID NOS: 1 to 4 may contain at least one RNase H inactive type nucleotide analog. The RNase H inactive type nucleotide analog may be ?-D-oxy-L-LNA, ?-D-ENA, R type cEt, 2?-OMe-nucleotide analog, and/or MOE-nucleotide analog.

Abstract: An information processing method includes: Step 1 of detecting a first SNP which is a mutation of an Alzheimer's disease-associated gene in a genomic DNA sample derived from a subject; and Step 2 of determining whether or not the subject will develop Alzheimer's disease from the first SNP using a machine learning model trained on a plurality of training datasets labeled with information on the onset of Alzheimer's disease for a second SNP, which is a mutation of the Alzheimer's disease-associated gene detected in a genomic DNA sample derived from a patient who has developed Alzheimer's disease.

Abstract: A positive electrode of a lithium secondary battery includes a sheet-like positive electrode current collector having conductivity, and a positive electrode active material plate that is a plate-like ceramic sintered compact joined to the positive electrode current collector via a conductive joint layer. The positive electrode active material plate includes at least one active material plate element. This at least one active material plate element is joined to the positive electrode current collector. A main surface of the active material plate element that opposes the positive electrode current collector includes a joint region in which the conductive joint layer exists between the positive electrode current collector and the active material plate element and a non-joint region in which the conductive joint layer does not exist between the positive electrode current collector and the active material plate element. The non joint region is arranged around the joint region.

Abstract: Disclosed is a switching valve having a small contact resistance when a valve body moves along a seating surface of a housing. In a switching valve which includes a valve body, coming into contact with a seating surface of a housing having a plurality of ports and selectively communicating at least two ports of the plurality of ports, and applies a fluid pressure to a back surface of the valve body, the switching valve includes a biasing member configured for biasing the valve body in a direction in which the valve body is moved away from the seating surface of the housing.

Abstract: The present invention provides novel antisense oligonucleotide pharmaceutical compositions having higher RNA aggregate-removing activity than conventional pharmaceutical compositions. The pharmaceutical composition of the present invention contains an oligonucleotide having any base sequence of a repeated sequence in which cytosine-adenine-guanine trinucleotides are repeated 5 to 13 times, from the 5? end to the 3? end, and the oligonucleotide has a mixmer structure containing at least two types of RNase H inactive nucleotide analogs. The present invention provides the pharmaceutical composition of the present invention used for the treatment of some symptoms of myotonic dystrophy type 1 disease.

Abstract: A cultured spherical body that is capable of easily performing quantitative analysis of a region containing brain neurons, useful as a supply source of neurons for transplantation, and can be used suitably for drug discovery screening for neurological diseases and compound evaluation systems is obtained. Provided are a cultured spherical body including a first cell layer containing neural stem cells and/or neural progenitor cells and a second cell layer containing brain neurons, wherein the first cell layer is present in the superficial portion of the cultured spherical body, and a method for producing the cultured spherical body.

Abstract: A resin composition for a medical device to be subjected to gas low-temperature sterilization includes a resin and an ion exchanger.

Abstract: An ultrasound endoscope includes: an ultrasound transducer including a piezoelectric element that includes a plurality of grooves with a groove filling material filled in the plurality of grooves, the groove filling material including the following (1) to (3): (1) an epoxy resin; (2) at least one filler selected from the group consisting of diamond, aluminum oxide, silicon oxide, silicon carbide, boron carbide, iron oxide (III), chromium oxide (III), and cubic boron nitride; and (3) an aliphatic diol diglycidyl ether.

Abstract: Provided is a valve with high pressure resistance. In a valve which is axially driven by a drive source to move a valve body to contact and separate from a valve seat in a valve chamber to control a fluid, a diaphragm has a center axially sandwiched by the valve body and a rod of the drive source and partitions the valve chamber and the drive source in a sealed state.

Abstract: The present invention derives from the unexpected finding that necroptosis is a novel biomarker and target for therapy in patients with liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). RIPK1, MLKL or RIPK3 can be detected and quantified in serum or plasma, and used as a biomarker for outcome in ACLF and other diseases involving aberrant necroptosis. By antagonising RIPK1, MLKL or RIPK3 many of the unwanted consequences or symptoms of acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL and RIPK3 that may be used in the treatment or prevention of ACLF. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL or RIPK3 that may be used in the treatment or prevention of aberrant necroptosis in the kidney, brain, liver or other organ of the body.

Abstract: An acoustic lens contains a base material composed of a diorganopolysiloxane or a silicone rubber compound utilizing a diorganopolysiloxane as a main component, and plate-like inorganic compound particles dispersed in the base material.

Abstract: The present invention provides a prophylactic and/or therapeutic agent for Alzheimer's disease containing a compound represented by the formula (I) or the formula (II) or a salt thereof.

Abstract: An expansion valve includes: a main body portion having a valve chamber and a valve seat; a case fixed to the main body portion; and a screw shaft that is driven by driving force of rotation obtained by reducing a rotational movement of a rotor due to the excitation of an excitation portion by a speed reduction mechanism to move a valve body forward and backward. A bellows configured to seal a gap between the inside of the case and the valve chamber is arranged in the valve chamber to be externally fitted onto the valve body, and the rotation of the valve body relative to the main body portion is restricted by a rotation restrictor.

Abstract: An information processing device includes: an acquirer configured to acquire images obtained by imaging cells differentiated from pluripotent stem cells derived from a subject; and a predictor configured to input the images acquired by the acquirer to a model trained on data in which information indicating at least a neurodegenerative disease is associated with the image obtained by imaging the cells of the neurodegenerative disease differentiated from the pluripotent stem cells, and predict an onset of the neurodegenerative disease of the subject or effects of drugs on the neurodegenerative disease, based on output results of the model to which the images were input.

Abstract: There is provided a damper device that can be held in a housing space with simple work. A damper device, which is disposed and used in a housing space formed in a device unit, includes: a damper body that is filled with gas and includes a diaphragm provided with a deformable-action portion formed at a central portion thereof; and an annular clip that holds an outer peripheral edge portion of the damper body and causes a biasing force to act on an inner wall of a cover member, which forms the housing space, in a radial direction.

Abstract: The present invention provides a prophylactic or therapeutic agent for Alzheimer's disease (AD) containing a combination of two or more compounds selected from the group consisting of compounds shown by compound Nos. 1 to 130. Since these compounds are existing drugs that have already been confirmed actually for safety and pharmacokinetics in human, they can be a means for a pre-emptive treatment of people at risk of AD and in a stage before developing mild cognitive impairment (MCI).

Abstract: A piston ring which is resinous includes an annular main body portion having an inner peripheral surface and an outer peripheral surface facing each other and a pair of side surfaces interconnecting the inner peripheral surface and the outer peripheral surface and a joint portion 3 formed in the main body portion. The joint portion has a step shape when viewed from at least one of the pair of side surfaces and the outer peripheral surface. The outer peripheral surface has a tapered surface having an outer diameter increasing from a side of one side surface of the pair of side surfaces of the main body portion toward a side of the other side surface.

Abstract: There is provided a damper device that can be held in a housing space with simple work. A damper device, which is disposed and used in a housing space formed in a device unit, includes: a damper body that is filled with gas and includes a diaphragm provided with a deformable-action portion formed at a central portion thereof; and an annular clip that holds an outer peripheral edge portion of the damper body and causes a biasing force to act on an inner wall of a cover member, which forms the housing space, in a radial direction.

Abstract: The present invention derives from the unexpected finding that necroptosis is a novel biomarker and target for therapy in patients with liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). RIPK1, MLKL or RIPK3 can be detected and quantified in serum or plasma, and used as a biomarker for outcome in ACLF and other diseases involving aberrant necroptosis. By antagonising RIPK1, MLKL or RIPK3 many of the unwanted consequences or symptoms of acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL and RIPK3 that may be used in the treatment or prevention of ACLF. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL or RIPK3 that may be used in the treatment or prevention of aberrant necroptosis in the kidney, brain, liver or other organ of the body.

Abstract: A positive electrode of a lithium secondary battery includes a sheet-like positive electrode current collector having conductivity, and a positive electrode active material plate that is a plate-like ceramic sintered compact joined to the positive electrode current collector via a conductive joint layer. The positive electrode active material plate includes at least one active material plate element. This at least one active material plate element is joined to the positive electrode current collector. A main surface of the active material plate element that opposes the positive electrode current collector includes a joint region in which the conductive joint layer exists between the positive electrode current collector and the active material plate element and a non-joint region in which the conductive joint layer does not exist between the positive electrode current collector and the active material plate element. The non joint region is arranged around the joint region.